Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or female patients (21 to 65 yrs)~2. Diagnosis of Schizophrenia or Schizoaffective Disorder~3. Outpatients~4. On stable doses of atypical antipsychotics, either Olanzapine, Clozapine, or Risperidone for at least 1 month~5. Patients can be on other concomitant medications. Patients can be on antipsychotic polypharmacy, but there should not be more than 1 of the above 3 atypicals in a single prescription.~6. Patients should be able to provide written informed consent.~7. Currently with a BMI ≥ 25 (Overweight) and/or ≥7% increase in weight from pre-antipsychotic treatment.~Exclusion Criteria:~1. Previous allergy to Aripiprazole/contraindication to use of Aripiprazole~2. Participants with current substance misuse, including alcohol but excluding tobacco.~3. Non-compliant with prescribed medications~4. Mental Retardation~5. Presence of any major or unstable medical or neurological illness (such as uncontrolled diabetes and hypertension).~6. Participant with an eating disorder~7. Participants with serious suicidal thoughts, or who pose a serious risk of harm to self or to others.~8. Women who are pregnant or breastfeeding~9. Severe Personality Disorder~10. Diagnosis of Hyper or Hypothyroidism; Evidence of thyroid dysfunction as evidenced by serum thyroid function tests (i.e Thyroid Stimulating Hormone and Free Thyroxine (fT4) levels \> 10 % above or below the limits of the normal range~11. Use of any medication for weight loss within the past one month to the study entry~12. Clinically significant abnormalities in physical examinations, ECG or lab assessments~13. Baseline BMI \< 18.5kg/m2 (cut-off point for underweight adults as per World Health Organisation guidelines)~14. Unable to read or speak English

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole Adjunct (Type: EXPERIMENTAL): Aripiprazole 5 mg as a fixed dose as adjunct to other antipsychotics

Based on this trial design, predict the completion outcome and termination type (if applicable).